June 18, 2021—Roche announced that the FDA granted emergency use authorization for the Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System. The singleplex, RT-PCR test screens within 20 minutes both asymptomatic and symptomatic persons. The test is for point-of-care use and offers broad strain coverage of SARS-CoV-2 variants, according to the company.
The Cobas SARS-CoV-2 Nucleic acid test is also available in markets that accept the CE mark and will be available in July.